Takeda Pharmaceutical Company Limited [TAK] Revenue clocked in at $29.98 billion, down -22.53% YTD: What’s Next?

Related

Takeda Pharmaceutical Company Limited [NYSE: TAK] loss -0.63% or -0.09 points to close at $14.10 with a heavy trading volume of 4039607 shares. The company report on October 13, 2021 that BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts.

First MA center will open in Worcester to support an urgent need for plasma donations used to develop therapies to treat a range of rare and chronic complex conditions.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


BioLife Plasma Services, part of the global biopharmaceutical company Takeda, announced the opening of a new plasma center in Worcester, MA, to help meet the urgent and growing demand for therapies developed from plasma. Plasma donations received at BioLife centers are used by Takeda to make established therapies that treat a range of rare and chronic complex diseases, such as immunodeficiency disorders, for which there are often no alternative treatments.

It opened the trading session at $14.13, the shares rose to $14.17 and dropped to $14.02, the range by which the price of stock traded the whole day. The daily chart for TAK points out that the company has recorded -16.86% loss over the past six months. However, it is still -0.5% lower than its most recent low trading price.

If we look at the average trading volume of 2.11M shares, TAK reached to a volume of 4039607 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Takeda Pharmaceutical Company Limited [TAK]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $21.65 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Takeda Pharmaceutical Company Limited shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 07, 2021. The new note on the price target was released on April 19, 2021, representing the official price target for Takeda Pharmaceutical Company Limited stock. Previously, the target price had yet another raise to $19.50, while Cowen analysts kept a Market Perform rating on TAK stock.

The Average True Range (ATR) for Takeda Pharmaceutical Company Limited is set at 0.28, with the Price to Sales ratio for TAK stock in the period of the last 12 months amounting to 1.51. The Price to Book ratio for the last quarter was 0.94, with the Price to Cash per share for the same quarter was set at 1.91.

Trading performance analysis for TAK stock

Takeda Pharmaceutical Company Limited [TAK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.05. With this latest performance, TAK shares dropped by -18.02% in over the last four-week period, additionally sinking by -16.86% over the last 6 months – not to mention a drop of -16.52% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 20.44, with the RSI for the last a single of trading hit 15.70, and the three-weeks RSI is set at 24.99 for Takeda Pharmaceutical Company Limited [TAK]. The present Moving Average for the last 50 days of trading for this stock 16.34, while it was recorded at 14.15 for the last single week of trading, and 17.12 for the last 200 days.

Takeda Pharmaceutical Company Limited [TAK]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Takeda Pharmaceutical Company Limited [TAK] shares currently have an operating margin of +14.00 and a Gross Margin at +56.24. Takeda Pharmaceutical Company Limited’s Net Margin is presently recorded at +11.76.

Return on Total Capital for TAK is now 4.38, given the latest momentum, and Return on Invested Capital for the company is 3.81. Return on Equity for this stock inclined to 7.60, with Return on Assets sitting at 2.92. When it comes to the capital structure of this company, Takeda Pharmaceutical Company Limited [TAK] has a Total Debt to Total Equity ratio set at 98.12. Additionally, TAK Total Debt to Total Capital is recorded at 49.53, with Total Debt to Total Assets ending up at 39.28. Long-Term Debt to Equity for the company is recorded at 96.72, with the Long-Term Debt to Total Capital now at 48.82.

Reflecting on the efficiency of the workforce at the company, Takeda Pharmaceutical Company Limited [TAK] managed to generate an average of $7,983,291 per employee. Receivables Turnover for the company is 4.00 with a Total Asset Turnover recorded at a value of 0.25.Takeda Pharmaceutical Company Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.50.

Takeda Pharmaceutical Company Limited [TAK]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Company Limited go to 0.58%.

An analysis of insider ownership at Takeda Pharmaceutical Company Limited [TAK]

There are presently around $1,354 million, or 3.10% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 15,492,997, which is approximately -17.226% of the company’s market cap and around 0.01% of the total institutional ownership; GLENVIEW CAPITAL MANAGEMENT, LLC, holding 9,115,521 shares of the stock with an approximate value of $128.53 million in TAK stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $75.95 million in TAK stock with ownership of nearly -0.931% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Takeda Pharmaceutical Company Limited stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 116 institutional holders increased their position in Takeda Pharmaceutical Company Limited [NYSE:TAK] by around 9,883,380 shares. Additionally, 145 investors decreased positions by around 22,959,112 shares, while 70 investors held positions by with 63,218,870 shares. The mentioned changes placed institutional holdings at 96,061,362 shares, according to the latest SEC report filing. TAK stock had 28 new institutional investments in for a total of 2,960,475 shares, while 45 institutional investors sold positions of 6,423,401 shares during the same period.